Aggrenox^© (ASS+Dipyridamol) nach Schlaganfall besser als ASS 100 mg?

 

 Buy Article Permissions and Reprints

Zusammenfassung

Einführung: Seit Jahren wird die Wertigkeit der Kombination Dipyridamol+ASS im Vergleich zur Standardtherapie ASS in der Sekundärprävention nach Schlaganfall kontrovers beurteilt. Anhand der sich aktuell veränderten Studienlage wird hier der Einsatz in der hausärztlichen Versorgung diskutiert.

Methode: Literaturrecherche und Analyse der vorliegenden Studien.

Ergebnisse: Es liegen 5 doppelblinde RCT mit gegensätzlichen Ergebnissen bei unterschiedlichen Dosierungen vor. Kürzlich wurde eine unverblindete RCT (ESPRIT) vorgelegt, die einen Benefit der Kombination vs. ASS zu bestätigen scheint. Bei dieser Studie sind aber designbedingte Verzerrungen nicht auszuschließen.

Schlussfolgerung: Der wissenschaftliche Nachweis einer Überlegenheit der Kombination Dipyridamol+ASS steht weiterhin aus. Bei schlechterer Verträglichkeit fehlt derzeit die Grundlage für eine Firstline-Empfehlung in der hausärztlichen Versorgung.

Abstract

Introduction: For years now opinions habe been divided as to the effectiveness of a combination of Dipyramidol+ASS as compared to the standard ASS treatment. In this paper, its use for secondary prevention of stroke in general practices is reviewed in the light of recent clinical trials.

Method: Systematic search and analysis of studies on this subject.

Findings: There are 5 doubleblinded RTCs showing contradictory results at different dosages. Another unblinded RTC (ESPRIT) - though possibly biased - shows an advantage of the combination over ASS.

Conclusion: There is still no sufficient evidence of the superiority of the combination. In view of lower drug compatibility its use as a first line line drug cannot be recommended for general practice.

Literatur

• 1 Diener HC. Primary and secondary stroke prevention with antiplatelet drugs.  Curr Pharm Des. 2006;  12 1293-1297
  CrossrefPubMedGoogle Scholar
• 2 Haberl R. ASS and dipyridamole combination. A decisive contribution to secondary prevention after stroke.  MMW Fortschr Med. 2003;  145 ((Suppl 2)) 98
  PubMedGoogle Scholar
• 3 No authors . Azetylsalizylsäure (ASS) plus Dipyridamol nach Insult.  Arznei-Telegramm. 2006;  37 55-56
  PubMedGoogle Scholar
• 4 Sacco RL, Adams R. et al . Stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.  Circulation. 2006;  113 e409-e449
  PubMedGoogle Scholar
• 5 Hensler S, Hoidn S, Jork K. Schlaganfall- 8. DEGAM-Leitlinie. Omikron-Verlag, Düsseldorf 2006
• 6 Kaye JA. A trial to evaluate the relative roles of dipyridamole and aspirin in the prevention of deep vein thrombosis in stroke patients. Bracknell, Böhringer Ingelheim (internal report) 1990
• 7 Guiraud-Chaumeil B, Rascol A, David J. et al . Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants.  Results of a 3-year controlled therapeutic trial Rev Neurol (Paris). 1982;  138 ((5)) 367-385
  PubMedGoogle Scholar
• 8 Bousser MG, Eschwege E, Haguenau M. et al . AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.  Stroke. 1983;  14 ((1)) 5-14
  CrossrefPubMedGoogle Scholar
• 9 The American-Canadian Co-Operative Study group . Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results.  Stroke. 1985;  16 ((3)) 406-415
  PubMedGoogle Scholar
• 10 Caneschi S, Bonaventi C, Finzi F. Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)].  Minerva Med. 1985;  76 ((41)) 1933-43
  PubMedGoogle Scholar
• 11 Diener HC, Cunha L, Forbes C. et al . A European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.  J Neurol Sci. 1996;  143 ((1-2)) 1-13
  CrossrefPubMedGoogle Scholar
• 12 Schryver EL De, Algra A, Gijn J van. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.  Cochrane Database Syst Rev. 2006;  , CD001820
  PubMedGoogle Scholar
• 13 Leonardi-Bee J, Bath PM, Bousser MG. et al . Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.  Stroke. 2005;  36 162-168
  CrossrefPubMedGoogle Scholar
• 14 Redman AR, Ryan GJ. Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke.  Clin Ther. 2001;  23 1391-1408
  CrossrefPubMedGoogle Scholar
• 15 ESPRIT Study Group . Halkes PH, Gijn J van, Kappelle LJ, Koudstaal PJ. et al . Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.  Lancet. 2006;  367 1665-1673
  CrossrefPubMedGoogle Scholar
• 16 Maxen A von, Wille H, Schoenhoefer PS. ESPRIT trial.  Lancet. 2006;  368 448-449 , author reply 449
  PubMedGoogle Scholar
• 17 Filippi A. ESPRIT trial.  Lancet. 2006;  368 447-448 , author reply 449
  PubMedGoogle Scholar
• 18 O'Donnell M, Eikelboom JW. ESPRIT trial.  Lancet. 2006;  368 447 , author reply 449
  PubMedGoogle Scholar
• 19 The Dutch TIA Trial Study Group . A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.  N Engl J Med. 1991;  325 1261-1266
  PubMedGoogle Scholar
• 20 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
  CrossrefPubMedGoogle Scholar
• 21 Heres S, Davis J, Maino K. et al . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.  Am J Psychiatry. 2006;  163 185-194
  CrossrefPubMedGoogle Scholar
• 22 Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.  J Nerv Ment Dis. 2002;  190 583-592
  CrossrefPubMedGoogle Scholar
• 23 Schröder K, Fabey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings.  Cochrane Database Syst Rev. 2004;  , CD004804. Review
  PubMedGoogle Scholar

Korrespondenzadresse

Dr. med. S. Hensler

Oppenheimer Landstr. 72

60596 Frankfurt

Email: stefan.hensler@gmx.net